Price T Rowe Associates Inc Nuvalent, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 858,161 shares of NUVL stock, worth $65.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
858,161
Previous 1,106,382
22.44%
Holding current value
$65.1 Million
Previous $81.4 Million
20.85%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding NUVL
# of Institutions
184Shares Held
54.4MCall Options Held
838KPut Options Held
116K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.52 Billion31.01% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.18MShares$317 Million11.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.41MShares$259 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.78MShares$211 Million4.39% of portfolio
-
Black Rock Inc. New York, NY2.71MShares$205 Million0.0% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.26B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...